CLINICAL TRIALS PROFILE FOR HYDELTRASOL

All Clinical Trials for Hydeltrasol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00900445 ↗	Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia	Withdrawn	National Cancer Institute (NCI)		2008-03-24	This clinical trial is studying body mass index in younger patients receiving prednisone/prednisolone, vincristine, daunorubicin, and pegaspargase for high-risk acute lymphoblastic leukemia. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the affect of body mass index on the way anticancer drugs work in the body. It may also help doctors predict how patients will respond to treatment
NCT00900445 ↗	Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia	Withdrawn	Children's Oncology Group		2008-03-24	This clinical trial is studying body mass index in younger patients receiving prednisone/prednisolone, vincristine, daunorubicin, and pegaspargase for high-risk acute lymphoblastic leukemia. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the affect of body mass index on the way anticancer drugs work in the body. It may also help doctors predict how patients will respond to treatment
NCT02828358 ↗	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2017-03-27	This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement. Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, vincristine sulfate, pegaspargase, hydrocortisone sodium succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin calcium, and thioguanine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug may kill more cancer cells.
NCT03007147 ↗	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Recruiting	EsPhALL network I-BFM Study Group	Phase 3	2017-07-28	This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
NCT03007147 ↗	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Recruiting	National Cancer Institute (NCI)	Phase 3	2017-07-28	This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
NCT03007147 ↗	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Recruiting	Children's Oncology Group	Phase 3	2017-07-28	This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
NCT03914625 ↗	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia	Recruiting	National Cancer Institute (NCI)	Phase 3	2019-06-28	This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexate, cytarabine, mercaptopurine, doxorubicin, cyclophosphamide, and thioguanine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin decreases the toxic effects of methotrexate. Giving monoclonal antibody therapy with chemotherapy may kill more cancer cells. Giving blinatumomab and combination chemotherapy may work better than combination chemotherapy alone in treating patients with B-ALL. This trial also assigns patients into different chemotherapy treatment regimens based on risk (the chance of cancer returning after treatment). Treating patients with chemotherapy based on risk may help doctors decide which patients can best benefit from which chemotherapy treatment regimens.

Clinical Trial Conditions for Hydeltrasol

Condition Name

Condition Name for Hydeltrasol
Intervention	Trials
B Acute Lymphoblastic Leukemia	5
Mixed Phenotype Acute Leukemia	3
Recurrent Mixed Phenotype Acute Leukemia	2
Untreated Childhood Acute Lymphoblastic Leukemia	2

Condition MeSH

Condition MeSH for Hydeltrasol
Intervention	Trials
Leukemia, Lymphoid	8
Leukemia	8
Precursor Cell Lymphoblastic Leukemia-Lymphoma	8
Acute Disease	4

Clinical Trial Locations for Hydeltrasol

Trials by Country

Trials by Country for Hydeltrasol
Location	Trials
United States	233
Canada	30
Australia	15
New Zealand	6
Puerto Rico	4

Trials by US State

Trials by US State for Hydeltrasol
Location	Trials
North Carolina	6
New Jersey	6
Florida	6
Delaware	6
California	6

Clinical Trial Progress for Hydeltrasol

Clinical Trial Phase

Clinical Trial Phase for Hydeltrasol
Clinical Trial Phase	Trials
Phase 3	6
Phase 2	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for Hydeltrasol
Clinical Trial Phase	Trials
Not yet recruiting	4
Recruiting	4
Active, not recruiting	1

Clinical Trial Sponsors for Hydeltrasol

Sponsor Name

Sponsor Name for Hydeltrasol
Sponsor	Trials
National Cancer Institute (NCI)	9
Children's Oncology Group	5
EsPhALL network I-BFM Study Group	1

Sponsor Type

Sponsor Type for Hydeltrasol
Sponsor	Trials
NIH	9
Other	6

Hydeltrasol Market Analysis and Financial Projection

Last updated: April 28, 2026

Hydeltrasol Clinical Trials Update, Market Analysis, and Projection

Hydeltrasol is not a drug name that can be reliably mapped to a specific marketed product, INN, clinical-trial registration entry, or publicly documented development pipeline based on the information provided. With no verifiable identifiers (active ingredient, sponsor, indication, dosage form, or trial registry IDs), a precise clinical-trials update and a defensible market projection cannot be produced.

What does the public record say about Hydeltrasol’s clinical development?

No verifiable, sourceable clinical-trials dataset can be tied to “Hydeltrasol” from the information available in this request. Without a scorable link to clinicaltrials.gov, EU CTR, Japan registry, or published sponsor pipelines, the following cannot be compiled in a way that meets an audit-grade standard:

• Trial phases (Phase 1-3), start/end dates, enrollment size
• Indications, endpoints, response rates, safety signals
• Sponsor and geography coverage
• Registration numbers and protocol versions
• Trial results timeline and regulatory readouts

What is Hydeltrasol’s market size and competitive landscape?

No defensible market model can be built because Hydeltrasol’s active ingredient and therapeutic target are not identified. That prevents construction of:

• Market definition (MOA-based or indication-based)
• TAM/SAM/SOM boundaries
• Competitor set (originators, biosimilars, generics, pipeline assets)
• Pricing anchor (WAC, NADAC, reimbursement categories, tender regimes)
• Uptake curve inputs (launch timing, payer evidence thresholds, switching risks)

What revenue projection can be made for Hydeltrasol?

A revenue projection requires at minimum:

• First commercial indication and geography
• Target population and expected share
• Launch year and uptake ramp
• Price and gross-to-net assumptions
• Competitor schedule and label differentiation

None of these parameters can be sourced for Hydeltrasol from the information provided, so no valid projection can be generated.

---

Key Takeaways

• Hydeltrasol cannot be mapped to a specific drug asset using the information provided, so no audit-grade clinical-trials update, market analysis, or revenue projection can be produced.
• A credible analysis requires a unique asset identifier (active ingredient/INN or registry-linked development program) to link clinical evidence and commercial assumptions to verifiable sources.

---

FAQs

1. What asset is Hydeltrasol?
   Hydeltrasol cannot be uniquely identified from the provided prompt.

2. Can you list Hydeltrasol trials by phase and indication?
   Not without a verifiable mapping to registered trial records or published protocols.

3. What market segment does Hydeltrasol target?
   The therapeutic class and indication are not specified in the prompt, so segment mapping is not possible.

4. When would Hydeltrasol likely launch, and at what revenue?
   Launch timing, dosing, price, and uptake inputs cannot be sourced for Hydeltrasol from the provided information.

5. Who are Hydeltrasol’s closest competitors?
   Competitor mapping requires the drug’s mechanism and indication, which are not provided.

---

References

[1] ClinicalTrials.gov. (accessed via query required for asset mapping).
[2] European Union Clinical Trials Register (accessed via query required for asset mapping).
[3] EMA product and pipeline databases (accessed via query required for asset mapping).
[4] FDA drug and biologics databases (accessed via query required for asset mapping).